Francesco Paolo Schena

List of Publications by Year
in descending order

272 papers	18,467 citations	13099 68 h-index	15266 126 g-index
285 all docs	285 docs citations	285 times ranked	15103 citing authors

#	Article	IF	Citations
1	The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney International, 2009, 76, 534-545.	5.2	1,028
2	Sirolimus for Kaposi's Sarcoma in Renal-Transplant Recipients. New England Journal of Medicine, 2005, 352, 1317-1323.	27.0	924
3	The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney International, 2009, 76, 546-556.	5.2	892
4	Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet, The, 1999, 354, 359-364.	13.7	800
5	Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial. Transplantation, 2009, 87, 233-242.	1.0	524
6	Pathogenetic Mechanisms of Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2005, 16, S30-S33.	6.1	463
7	IgA nephropathy. Nature Reviews Disease Primers, 2016, 2, 16001.	30.5	322
8	Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ: British Medical Journal, 2004, 329, 828.	2.3	318
9	IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22â€“23. Nature Genetics, 2000, 26, 354-357.	21.4	291
10	Disease-associated Bias in T Helper Type 1 (Th1)/Th2 CD4+ T Cell Responses Against MAGE-6 in HLA-DRB1*0401+ Patients With Renal Cell Carcinoma or Melanoma. Journal of Experimental Medicine, 2002, 196, 619-628.	8.5	290
11	The Number, Quality, and Coverage of Randomized Controlled Trials in Nephrology. Journal of the American Society of Nephrology: JASN, 2004, 15, 411-419.	6.1	285
12	A Randomized, Multicenter Study of Steroid Avoidance, Early Steroid Withdrawal or Standard Steroid Therapy in Kidney Transplant Recipients. American Journal of Transplantation, 2008, 8, 307-316.	4.7	274
13	Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrology Dialysis Transplantation, 2009, 24, 3694-3701.	0.7	256
14	Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy. Kidney International, 2004, 66, 1570-1577.	5.2	243
15	Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes and Endocrinology,the, 2019, 7, 128-139.	11.4	223
16	Long-Term Benefits with Sirolimus-Based Therapy after Early Cyclosporine Withdrawal. Journal of the American Society of Nephrology: JASN, 2004, 15, 809-817.	6.1	221
17	Survey of the Italian Registry of Renal Biopsies. Frequency of the renal diseases for 7 consecutive years. The Italian Group of Renal Immunopathology. Nephrology Dialysis Transplantation, 1997, 12, 418-426.	0.7	205
18	Epidemiology of IgA Nephropathy: A Global Perspective. Seminars in Nephrology, 2018, 38, 435-442.	1.6	204

#	Article	IF	Citations
19	Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics, 2009, 10, 388.	2.8	202
20	Lower Malignancy Rates in Renal Allograft Recipients Converted to Sirolimus-Based, Calcineurin Inhibitor-Free Immunotherapy: 24-Month Results From the CONVERT Trial. Transplantation, 2011, 92, 303-310.	1.0	198
21	The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney International, 2010, 77, 921-927.	5.2	181
22	Abnormal miR-148b Expression Promotes Aberrant Glycosylation of IgA1 in IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2012, 23, 814-824.	6.1	176
23	Long-term prognosis of Henoch-Schonlein nephritis in adults and children. Nephrology Dialysis Transplantation, 1997, 12, 2277-2283.	0.7	168
24	The treatment of chronic hepatitis C with peginterferon alfa-2a (40kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. Journal of Hepatology, 2007, 46, 768-774.	3.7	163
25	Catheter-Related Interventions to Prevent Peritonitis in Peritoneal Dialysis. Journal of the American Society of Nephrology: JASN, 2004, 15, 2735-2746.	6.1	161
26	Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination1, 2. Transplantation, 2002, 74, 1560-1567.	1.0	158
27	Maturation of dendritic cells abrogates C1q production in vivo and in vitro. Blood, 2004, 103, 3813-3820.	1.4	157
28	Risk of de novo cancers after transplantation: Results from a cohort of 7217 kidney transplant recipients, Italy 1997â€“2009. European Journal of Cancer, 2013, 49, 336-344.	2.8	157
29	Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis. Hepatology, 1997, 25, 1237-1244.	7.3	155
30	A Novel Simpler Histological Classification for Renal Survival in IgA Nephropathy: A Retrospective Study. American Journal of Kidney Diseases, 2007, 49, 763-775.	1.9	153
31	FTY720 versus MMF with Cyclosporine in de novo Renal Transplantation: A 1-Year, Randomized Controlled Trial in Europe and Australasia. American Journal of Transplantation, 2006, 6, 2912-2921.	4.7	145
32	MCP-1 and EGF renal expression and urine excretion in human congenital obstructive nephropathy. Kidney International, 2000, 58, 182-192.	5.2	144
33	Hemoglobin Targets for the Anemia of Chronic Kidney Disease: A Meta-analysis of Randomized, Controlled Trials. Journal of the American Society of Nephrology: JASN, 2004, 15, 3154-3165.	6.1	142
34	Therapeutic Targeting of Classical and Lectin Pathways of Complement Protects from Ischemia-Reperfusion-Induced Renal Damage. American Journal of Pathology, 2010, 176, 1648-1659.	3.8	136
35	The Italian experience of the national registry of renal biopsies. Kidney International, 2004, 66, 890-894.	5.2	132
36	A comparison of DNA extraction methods for food analysis. Food Control, 2007, 18, 76-80.	5.5	132

#	Article	IF	Citations
37	Epidemiology of end-stage renal disease: International comparisons of renal replacement therapy. Kidney International, 2000, 57, S39-S45.	5.2	122
38	Expression of epidermal growth factor and its receptor in normal and diseased human kidney: An immunohistochemical and in situ hybridization study. Kidney International, 1996, 49, 656-665.	5.2	121
39	Immature myeloid and plasmacytoid dendritic cells infiltrate renal tubulointerstitium in patients with lupus nephritis. Molecular Immunology, 2008, 45, 259-265.	2.2	121
40	MONOCYTE CHEMOTACTIC PEPTIDE-1 EXPRESSION AND MONOCYTE INFILTRATION IN ACUTE RENAL TRANSPLANT REJECTION1. Transplantation, 1997, 63, 414-420.	1.0	121
41	Clinical relevance of cytokine production in hemodialysis. Kidney International, 2000, 58, S104-S111.	5.2	120
42	Rapamycin for Treatment of Chronic Allograft Nephropathy in Renal Transplant Patients. Journal of the American Society of Nephrology: JASN, 2005, 16, 3755-3762.	6.1	115
43	Genetic Heterogeneity in Italian Families with IgA Nephropathy: Suggestive Linkage for Two Novel IgA Nephropathy Loci. American Journal of Human Genetics, 2006, 79, 1130-1134.	6.2	111
44	TLR2 plays a role in the activation of human resident renal stem/progenitor cells. FASEB Journal, 2010, 24, 514-525.	0.5	107
45	Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation, 2003, 76, 903-908.	1.0	103
46	Expression of platelet-derived growth factor receptors in normal and diseased human kidney. An immunohistochemistry and in situ hybridization study.. Journal of Clinical Investigation, 1994, 94, 50-58.	8.2	97
47	Urinary IL-6/EGF ratio: A useful prognostic marker for the progression of renal damage in IgA nephropathy. Kidney International, 1996, 50, 1990-2001.	5.2	94
48	The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy. Kidney International, 2008, 73, 327-333.	5.2	94
49	Desmopressin Acetate in Percutaneous Ultrasound-Guided Kidney Biopsy: A Randomized Controlled Trial. American Journal of Kidney Diseases, 2011, 57, 850-855.	1.9	93
50	Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection. Clinical and Experimental Immunology, 2005, 140, 498-506.	2.6	92
51	Ischemia-Reperfusion Induces Glomerular and Tubular Activation of Proinflammatory and Antiapoptotic Pathways. Journal of the American Society of Nephrology: JASN, 2004, 15, 2675-2686.	6.1	91
52	Addition of Sirolimus to Cyclosporine Delays the Recovery from Delayed Graft Function but Does not Affect 1-Year Graft Function. Journal of the American Society of Nephrology: JASN, 2004, 15, 228-233.	6.1	87
53	A general multiplex-PCR assay for the general detection of genetically modified soya and maize. Food Control, 2005, 16, 535-539.	5.5	87
54	IMMUNOLOGIC EVALUATION DURING THE FIRST YEAR OF LIFE OF INFANTS BORN TO CYCLOSPORINE-TREATED FEMALE KIDNEY TRANSPLANT RECIPIENTS. Transplantation, 2000, 69, 2049-2054.	1.0	86

#	Article	IF	Citations
55	Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis. American Journal of Kidney Diseases, 2016, 68, 392-401.	1.9	85
56	Progression of renal damage in human glomerulonephritides: Is there sleight of hand in winning the game?. Kidney International, 1997, 52, 1439-1457.	5.2	82
57	Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors. Nephrology Dialysis Transplantation, 2007, 22, i17-i22.	0.7	82
58	Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells. Kidney International, 1999, 56, 461-470.	5.2	79
59	Altered modulation of WNTâ€“Î²-catenin and PI3K/Akt pathways in IgA nephropathy. Kidney International, 2010, 78, 396-407.	5.2	78
60	Immunosuppressive treatments for immunoglobulin A nephropathy: A metaâ€analysis of randomized controlled trials. Nephrology, 2004, 9, 177-185.	1.6	76
61	Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation, 2003, 75, 998-1003.	1.0	74
62	Antihypertensive Agents for Primary Prevention of Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2005, 16, 3081-3091.	6.1	74
63	Protease-Activated Receptor-2 Expression in IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2003, 14, 2072-2083.	6.1	73
64	INTERFERENCE OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS ON ERYTHROPOIESIS IN KIDNEY TRANSPLANT RECIPIENTS. Transplantation, 1997, 64, 913-918.	1.0	73
65	MicroRNAs in kidney diseases: new promising biomarkers for diagnosis and monitoring. Nephrology Dialysis Transplantation, 2014, 29, 755-763.	0.7	72
66	The possible role of ChemR23/Chemerin axis in the recruitment of dendritic cells in lupus nephritis. Kidney International, 2011, 79, 1228-1235.	5.2	71
67	Increased Risk of End-Stage Renal Disease in Familial IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2002, 13, 453-460.	6.1	71
68	An â€œevidence-basedâ€•survey of therapeutic options for IgA nephropathy: assessment and criticism. American Journal of Kidney Diseases, 2003, 41, 1129-1139.	1.9	70
69	A Bioartificial Renal Tubule Device Embedding Human Renal Stem/Progenitor Cells. PLoS ONE, 2014, 9, e87496.	2.5	69
70	Immune modulation of human dendritic cells by complement. European Journal of Immunology, 2007, 37, 2803-2811.	2.9	67
71	ACE gene polymorphism and IgA nephropathy: An ethnically homogeneous study and a meta-analysis. Kidney International, 2001, 60, 732-740.	5.2	66
72	IL-17 Expression by Tubular Epithelial Cells in Renal Transplant Recipients with Acute Antibody-Mediated Rejection. American Journal of Transplantation, 2011, 11, 1248-1259.	4.7	65

#	Article	IF	Citations
73	Sirolimus Interferes with Iron Homeostasis in Renal Transplant Recipients. Transplantation, 2006, 82, 908-912.	1.0	62
74	Renal Cell Carcinoma: A Study through NMR-Based Metabolomics Combined with Transcriptomics. Diseases (Basel, Switzerland), 2016, 4, 7.	2.5	62
75	In a retrospective international study, circulating miR-148b and let-7b were found to be serum markers for detecting primary IgA nephropathy. Kidney International, 2016, 89, 683-692.	5.2	61
76	Infiltrating dendritic cells contribute to local synthesis of C1q in murine and human lupus nephritis. Molecular Immunology, 2010, 47, 2129-2137.	2.2	60
77	An end stage kidney disease predictor based on an artificial neural networks ensemble. Expert Systems With Applications, 2013, 40, 4438-4445.	7.6	60
78	Role of let-7b in the regulation ofN-acetylgalactosaminyltransferase 2 in IgA nephropathy. Nephrology Dialysis Transplantation, 2015, 30, 1132-1139.	0.7	60
79	Role of Blood Pressure Targets and Specific Antihypertensive Agents Used to Prevent Diabetic Nephropathy and Delay Its Progression: Table 1.. Journal of the American Society of Nephrology: JASN, 2006, 17, S153-S155.	6.1	58
80	Sirolimus and Proteinuria in Renal Transplant Patients: Evidence for a Dose-Dependent Effect on Slit Diaphragm-Associated Proteins. Transplantation, 2011, 91, 997-1004.	1.0	58
81	Downregulation of Nuclear-Encoded Genes of Oxidative Metabolism in Dialyzed Chronic Kidney Disease Patients. PLoS ONE, 2013, 8, e77847.	2.5	58
82	FTY720 Versus Mycophenolate Mofetil in De Novo Renal Transplantation: Six-Month Results of a Double-Blind Study. Transplantation, 2007, 84, 885-892.	1.0	57
83	Human renal stem/progenitor cells repair tubular epithelial cell injury through TLR2-driven inhibin-A and microvesicle-shuttled decorin. Kidney International, 2013, 83, 392-403.	5.2	57
84	Trapidil inhibits human mesangiai cell proliferation: Effect on PDGF Î²-receptor binding and expression. Kidney International, 1994, 46, 1002-1009.	5.2	56
85	Bone morphogenetic protein-2 may represent the molecular link between oxidative stress and vascular stiffness in chronic kidney disease. Atherosclerosis, 2010, 211, 418-423.	0.8	56
86	Immunosuppressive agents for treating IgA nephropathy. The Cochrane Library, 2015, , CD003965.	2.8	54
87	Treatment of proteinuric idiopathic glomerulonephritides in adults: A retrospective survey. American Journal of Medicine, 1988, 85, 315-326.	1.5	53
88	PROTEASE-ACTIVATED RECEPTOR 1 AND PLASMINOGEN ACTIVATOR INHIBITOR 1 EXPRESSION IN CHRONIC ALLOGRAFT NEPHROPATHY. Transplantation, 2001, 72, 1437-1443.	1.0	52
89	Superior Outcomes in Renal Transplantation after Early Cyclosporine Withdrawal and Sirolimus Maintenance Therapy, Regardless of Baseline Renal Function. Transplantation, 2005, 80, 1204-1211.	1.0	52
90	Worldwide distribution of glomerular diseases: the role of renal biopsy registries. Nephrology Dialysis Transplantation, 2010, 25, 334-336.	0.7	51

#	Article	IF	Citations
91	MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clinical Cancer Research, 2003, 9, 947-54.	7.0	51
92	Increase of Proliferating Renal Progenitor Cells in Acute Tubular Necrosis Underlying Delayed Graft Function. Transplantation, 2008, 85, 1112-1119.	1.0	50
93	Rapamycin Inhibits PAI-1 Expression and Reduces Interstitial Fibrosis and Glomerulosclerosis in Chronic Allograft Nephropathy. Transplantation, 2008, 85, 125-134.	1.0	49
94	Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study. Nephrology Dialysis Transplantation, 2012, 27, 3560-3567.	0.7	49
95	Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arthritis and Rheumatism, 2005, 52, 2519-2520.	6.7	48
96	AQP5 Is Expressed In Type-B Intercalated Cells in the Collecting Duct System of the Rat, Mouse and Human Kidney. Cellular Physiology and Biochemistry, 2011, 28, 683-692.	1.6	48
97	Activated innate immunity and the involvement of CX3CR1â€“fractalkine in promoting hematuria in patients with IgA nephropathy. Kidney International, 2012, 82, 548-560.	5.2	48
98	Cultivar classification of Apulian olive oils: Use of artificial neural networks for comparing NMR, NIR and merceological data. Food Chemistry, 2017, 219, 131-138.	8.2	48
99	Increased production of interleukin-2 and IL-2 receptor in primary IgA nephropathy. Kidney International, 1989, 35, 875-879.	5.2	47
100	Development and testing of an artificial intelligence tool for predicting end-stage kidney disease in patients with immunoglobulin A nephropathy. Kidney International, 2021, 99, 1179-1188.	5.2	47
101	miR-1915 and miR-1225-5p Regulate the Expression of CD133, PAX2 and TLR2 in Adult Renal Progenitor Cells. PLoS ONE, 2013, 8, e68296.	2.5	46
102	Rapamycin-Induced Hypophosphatemia and Insulin Resistance Are Associated With mTORC2 Activation and Klotho Expression. American Journal of Transplantation, 2011, 11, 1656-1664.	4.7	45
103	Monocyte recruitment in cryoglobulinemic membranoproliferative glomerulonephritis: A pathogenetic role for monocyte chemotactic peptide-1. Kidney International, 1997, 51, 155-163.	5.2	44
104	Regenerative and Proinflammatory Effects of Thrombin on Human Proximal Tubular Cells. Journal of the American Society of Nephrology: JASN, 2000, 11, 1016-1025.	6.1	44
105	The role of hyperparathyroidism, erythropoietin therapy, and CMV infection in the failure of arteriovenous fistula in hemodialysis. Kidney International, 2003, 64, 715-719.	5.2	43
106	Role of interferon-Î³ gene polymorphisms in susceptibility to IgA nephropathy: a family-based association study. European Journal of Human Genetics, 2006, 14, 488-496.	2.8	43
107	Ischemiaâ€“reperfusion injury-induced abnormal dendritic cell traffic in the transplanted kidney with delayed graft function. Kidney International, 2007, 72, 994-1003.	5.2	43
108	Antimicrobial agents to prevent peritonitis in peritoneal dialysis: a systematic review of randomized controlled trials. American Journal of Kidney Diseases, 2004, 44, 591-603.	1.9	43

#	Article	IF	Citations
109	Tissue factor, plasminogen activator inhibitor-1, and thrombin receptor expression in human crescentic glomerulonephritis. American Journal of Kidney Diseases, 2000, 35, 726-738.	1.9	42
110	Efficacy and Safety Outcomes Among De Novo Renal Transplant Recipients Managed by C2 Monitoring of Cyclosporine A Microemulsion: Results of a 12-Month, Randomized, Multicenter Study. Transplantation, 2005, 79, 577-583.	1.0	42
111	1H Nuclear Magnetic Resonance Study of Olive Oils Commercially Available as Italian Products in the United States of America. Nutrients, 2012, 4, 343-355.	4.1	41
112	The Three-Gene Signature in Urinary Extracellular Vesicles from Patients with Clear Cell Renal Cell Carcinoma. Journal of Cancer, 2016, 7, 1960-1967.	2.5	41
113	Interleukin-6, interleukin-8 and monocyte chemotactic peptide-1 gene expression and protein synthesis are independently modulated by hemodialysis membranes. Kidney International, 1998, 54, 570-579.	5.2	40
114	COVID-19 and kidney transplantation: an Italian Survey and Consensus. Journal of Nephrology, 2020, 33, 667-680.	2.0	40
115	Immunosuppressive agents for treating IgA nephropathy. The Cochrane Library, 2020, 3, CD003965.	2.8	40
116	Immunogenetic aspects of primary IgA nephropathy. Kidney International, 1995, 48, 1998-2013.	5.2	39
117	A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine. Nephrology Dialysis Transplantation, 2007, 23, 707-714.	0.7	39
118	T helper 1, 2 and 17 cell subsets in renal transplant patients with delayed graft function. Transplant International, 2011, 24, 233-242.	1.6	39
119	Aberrantly methylated DNA regions lead to low activation of CD4+ T-cells in IgA nephropathy. Clinical Science, 2016, 130, 733-746.	4.3	39
120	A Randomized, Open-Label Study of Sirolimus Versus Cyclosporine in Primary De Novo Renal Allograft Recipients. Transplantation, 2013, 95, 1233-1241.	1.0	38
121	Robustness of NMR-based metabolomics to generate comparable data sets for olive oil cultivar classification. An inter-laboratory study on Apulian olive oils. Food Chemistry, 2016, 199, 675-683.	8.2	38
122	Clinical decision support system for end-stage kidney disease risk estimation in IgA nephropathy patients. Nephrology Dialysis Transplantation, 2016, 31, 80-86.	0.7	38
123	CD40L Proinflammatory and Profibrotic Effects on Proximal Tubular Epithelial Cells. Journal of the American Society of Nephrology: JASN, 2006, 17, 627-636.	6.1	37
124	Kaposiâ€™s sarcoma and mTOR: a crossroad between viral infection neoangiogenesis and immunosuppression. Transplant International, 2008, 21, 825-832.	1.6	37
125	Dendritic cells and complement: at the cross road of innate and adaptive immunity. Molecular Immunology, 2004, 41, 133-140.	2.2	36
126	Local Activation of Interleukin 6 Signaling Is Associated With Arteriovenous Fistula Stenosis in Hemodialysis Patients. American Journal of Kidney Diseases, 2007, 49, 664-673.	1.9	36

#	Article	IF	Citations
127	Extended Criteria Donor Kidney Transplantation: Comparative Outcome Analysis Between Single versus Double Kidney Transplantation at 5 Years. Transplantation Proceedings, 2010, 42, 1104-1107.	0.6	36
128	Hypertension is an independent predictor of delayed graft function and worse renal function only in kidneys with chronic pathological lesions. Transplantation, 2002, 73, 623-627.	1.0	34
129	Confocal Laser Scanning Microscope Study of Terminal Villi Vessels in Normal Term and Pre-eclamptic Placentas. Placenta, 2006, 27, 735-739.	1.5	33
130	High pretransplant serum levels of CXCL9 are associated with increased risk of acute rejection and graft failure in kidney graft recipients. Transplant International, 2010, 23, 465-475.	1.6	33
131	Multivariate Analysis of 1H-NMR Spectra of Genetically Characterized Extra Virgin Olive Oils and Growth Soil Correlations. JAOCS, Journal of the American Oil Chemists' Society, 2011, 88, 1463-1475.	1.9	33
132	BMP-2 induces a profibrotic phenotype in adult renal progenitor cells through Nox4 activation. American Journal of Physiology - Renal Physiology, 2012, 303, F23-F34.	2.7	33
133	Biosynthesis of C3 by human mesangial cells. Modulation by proinflammatory cytokines. Kidney International, 1995, 47, 829-836.	5.2	32
134	Dialysis-related systemic microinflammation is associated with specific genomic patterns. Nephrology Dialysis Transplantation, 2008, 23, 1673-1681.	0.7	32
135	Classification and chemometric study of Southern Italy monovarietal wines based on NMR and HPLC-DAD-MS. Food Science and Biotechnology, 2015, 24, 817-826.	2.6	32
136	Complement Deficiency and Antibody Profile in Survivors of Meningococcal Meningitis due to common Serogroups in Italy. Scandinavian Journal of Immunology, 1992, 35, 589-596.	2.7	31
137	No evidence for a role of cosmc-chaperone mutations in European IgA nephropathy patients. Nephrology Dialysis Transplantation, 2008, 24, 321-324.	0.7	30
138	Genetic variant of C1GalT1 contributes to the susceptibility to IgA nephropathy. Journal of Nephrology, 2009, 22, 152-9.	2.0	30
139	Immunoglobulin a nephropathy with mild renal lesions: a call in the forest for physicians and nephrologists. American Journal of Medicine, 2001, 110, 499-500.	1.5	29
140	From -omics to personalized medicine in nephrology: integration is the key. Nephrology Dialysis Transplantation, 2013, 28, 24-28.	0.7	29
141	Renal C3 synthesis in idiopathic membranous nephropathy: Correlation to urinary C5b-9 excretion. Kidney International, 2000, 57, 137-146.	5.2	28
142	Inhibin-A and Decorin Secreted by Human Adult Renal Stem/Progenitor Cells Through the TLR2 Engagement Induce Renal Tubular Cell Regeneration. Scientific Reports, 2017, 7, 8225.	3.3	28
143	Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis. American Journal of Kidney Diseases, 2021, 78, 340-349.e1.	1.9	28
144	In Vivo Modulation of Soluble â€œAntagonisticâ€•IL-6 Receptor Synthesis and Release in ESRD. Journal of the American Society of Nephrology: JASN, 2005, 16, 1099-1107.	6.1	27

#	Article	IF	Citations
145	Nonadherence to immunosuppressive therapy in kidney transplant recipients: can technology help?. Journal of Nephrology, 2016, 29, 627-636.	2.0	27
146	Thin glomerular basement membrane disease: clinical significance of a morphological diagnosis--a collaborative study of the Italian Renal Immunopathology Group. Nephrology Dialysis Transplantation, 2005, 20, 545-551.	0.7	26
147	Inflammation and carnitine in hemodialysis patients. , 2005, 15, 8-12.		26
148	Sirolimus-Based Therapy With or Without Cyclosporine: Long-Term Follow-up in Renal Transplant Patients. Transplantation Proceedings, 2005, 37, 693-696.	0.6	26
149	Altered monocyte expression and expansion of non-classical monocyte subset in IgA nephropathy patients. Nephrology Dialysis Transplantation, 2015, 30, 1122-1132.	0.7	26
150	Pregnancy in renal transplantation: immunologic evaluation of neonates from mothers with transplanted kidney. Transplant Immunology, 2002, 9, 161-164.	1.2	25
151	jun-N-terminal kinase regulates thrombin-induced PAI-1 gene expression in proximal tubular epithelial cells. Kidney International, 2004, 65, 2249-2261.	5.2	25
152	Monitoring Biological Action of Rapamycin in Renal Transplantation. American Journal of Kidney Diseases, 2007, 50, 314-325.	1.9	25
153	IgA Nephropathy: A Disease in Search of a Large-Scale Clinical Trial to Reliably Inform Practice. American Journal of Kidney Diseases, 2009, 53, 5-8.	1.9	25
154	Management of patients with chronic kidney disease. Internal and Emergency Medicine, 2011, 6, 77-83.	2.0	25
155	Renal expression of monocyte chemotactic protein-1 and epidermal growth factor in children with obstructive hydronephrosis. Journal of Pediatric Surgery, 2000, 35, 569-572.	1.6	24
156	Vitamin E-modified filters modulate Jun N-terminal kinase activation in peripheral blood mononuclear cells. Kidney International, 2002, 62, 602-610.	5.2	24
157	The IgA nephropathy Biobank. An important starting point for the genetic dissection of a complex trait. BMC Nephrology, 2005, 6, 14.	1.8	24
158	CD40 Ligand Increases Complement C3 Secretion by Proximal Tubular Epithelial Cells. Journal of the American Society of Nephrology: JASN, 2005, 16, 2003-2011.	6.1	23
159	IgA Nephropathy: The Presence of Familial Disease Does Not Confer an Increased Risk for Progression. American Journal of Kidney Diseases, 2006, 47, 761-769.	1.9	23
160	Serum Fetuin A in Hemodialysis: A Link Between Derangement of Calcium-Phosphorus Homeostasis and Progression of Atherosclerosis?. American Journal of Kidney Diseases, 2009, 53, 467-474.	1.9	23
161	Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients. Clinical and Experimental Immunology, 2010, 159, 268-280.	2.6	23
162	Genome-wide scan identifies a copy number variable region at 3p21.1 that influences the TLR9 expression levels in IgA nephropathy patients. European Journal of Human Genetics, 2015, 23, 940-948.	2.8	23

#	Article	IF	Citations
163	Omics studies for comprehensive understanding of immunoglobulin A nephropathy: state-of-the-art and future directions. Nephrology Dialysis Transplantation, 2018, 33, 2101-2112.	0.7	23
164	Sirolimus and angiotensin-converting enzyme inhibitors together induce tongue oedema in renal transplant recipients. Nephrology Dialysis Transplantation, 2004, 19, 2906-2908.	0.7	22
165	A Randomized Trial of Steroid Avoidance in Renal Transplant Patients Treated with Everolimus and Cyclosporine. Transplantation Proceedings, 2005, 37, 788-790.	0.6	22
166	Long term follow-up of women with hypertension in pregnancy. International Journal of Gynecology and Obstetrics, 1988, 27, 45-49.	2.3	21
167	Pentraxin 3 and complement cascade activation in the failure of arteriovenous fistula. Atherosclerosis, 2010, 209, 241-247.	0.8	21
168	Potential Reparative Role of Resident Adult Renal Stem/Progenitor Cells in Acute Kidney Injury. BioResearch Open Access, 2015, 4, 326-333.	2.6	21
169	A Narrative Review on C3 Glomerulopathy: A Rare Renal Disease. International Journal of Molecular Sciences, 2020, 21, 525.	4.1	21
170	microRNAs in glomerular diseases from pathophysiology to potential treatment target. Clinical Science, 2015, 128, 775-788.	4.3	20
171	Clinical Application of Human Urinary Extracellular Vesicles in Kidney and Urologic Diseases. International Journal of Molecular Sciences, 2016, 17, 1043.	4.1	20
172	Coagulation Cascade Activation Causes CC Chemokine Receptor-2 Gene Expression and Mononuclear Cell Activation in Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2005, 16, 2477-2486.	6.1	19
173	Î±- and Î²-Adducin polymorphisms affect podocyte proteins and proteinuria in rodents and decline of renal function in human IgA nephropathy. Journal of Molecular Medicine, 2010, 88, 203-217.	3.9	19
174	The Anti-Fibrotic Effect of Mycophenolic Acidâ€“Induced Neutral Endopeptidase. Journal of the American Society of Nephrology: JASN, 2010, 21, 2157-2168.	6.1	19
175	Patient classification and outcome prediction in IgA nephropathy. Computers in Biology and Medicine, 2015, 66, 278-286.	7.0	19
176	Clinical and therapeutic aspects of diabetic nephropathy. Journal of Nephrology, 2003, 16, 487-99.	2.0	19
177	Renal Growth Factors: Past, Present and Future. American Journal of Nephrology, 1999, 19, 308-312.	3.1	18
178	Immunosuppressive agents for treating IgA nephropathy. , 2003, , CD003965.		18
179	Analysis of the factors conditioning the diffusion of peritoneal dialysis in Italy. Nephrology Dialysis Transplantation, 2007, 22, 3601-3605.	0.7	18
180	Dexamethasone modulates interleukinâ€12 production by inducing monocyte chemoattractant proteinâ€1 in human dendritic cells. Immunology and Cell Biology, 2007, 85, 610-616.	2.3	18

#	Article	IF	Citations
181	ID2-VEGF-related Pathways in the Pathogenesis of Kaposiâ€™s Sarcoma: A Link Disrupted by Rapamycin. American Journal of Transplantation, 2009, 9, 558-566.	4.7	18
182	Following the olive oil production chain: 1D and 2D NMR study of olive paste, pomace, and oil. European Journal of Lipid Science and Technology, 2014, 116, 1513-1521.	1.5	18
183	A transcriptomics study of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology, 2018, 142, 883-891.	2.9	18
184	One-year angiotensin-converting enzyme inhibition plus mycophenolate mofetil immunosuppression in the course of early IgA nephropathy: a multicenter, randomised, controlled study. Journal of Nephrology, 2005, 18, 136-40.	2.0	18
185	Potential role of effector memory T cells in chronic T cell-mediated kidney graft rejection. Nephrology Dialysis Transplantation, 2016, 31, 2131-2142.	0.7	17
186	Captopril enhances transforming growth factor (tgf)-??1 expression in peripheral blood mononuclear cells: a mechanism independent from angiotensin converting enzyme inhibition? A study in cyclosporine-treated kidney-transplanted patients. Transplantation, 2002, 74, 1710-1715.	1.0	16
187	Cis and trans regulatory elements in NPHS2 promoter: Implications in proteinuria and progression of renal diseases. Kidney International, 2006, 70, 1332-1341.	5.2	16
188	Immunohistochemical characterization of glomerular and tubulointerstitial infiltrates in renal transplant patients with chronic allograft dysfunction. Nephrology Dialysis Transplantation, 2010, 25, 4071-4077.	0.7	16
189	Search for genetic association between IgA nephropathy and candidate genes selected by function or by gene mapping at loci IGAN2 and IGAN3. Nephrology Dialysis Transplantation, 2012, 27, 2328-2337.	0.7	16
190	Urinary procoagulant and fibrinolytic activity in human glomerulonephritis. Relationship with renal function. Kidney International, 1991, 39, 1213-1217.	5.2	15
191	Vasoactive intestinal polypeptide (VIP) is not an androgen-dependent neuromediator of penile erection. International Journal of Impotence Research, 2005, 17, 23-26.	1.8	15
192	<scp>NMR</scp>â€based metabolomic approach for <scp>EVOO</scp> from secular olive trees of Apulia region. European Journal of Lipid Science and Technology, 2013, 115, 1043-1052.	1.5	15
193	Thrombin: A Novel Renal Growth Factor. Nephron Experimental Nephrology, 1999, 7, 20-25.	2.2	14
194	Monitoring of Inosine Monophosphate Dehydrogenase Activity and Expression during the Early Period of Mycophenolate Mofetil Therapy in De Novo Renal Transplant Patients. Drug Metabolism and Pharmacokinetics, 2013, 28, 109-117.	2.2	14
195	Transcriptomics in kidney biopsy is an untapped resource for precision therapy in nephrology: a systematic review. Nephrology Dialysis Transplantation, 2018, 33, 1094-1102.	0.7	14
196	Catheter type, placement and insertion techniques for preventing catheter-related infections in chronic peritoneal dialysis patients. The Cochrane Library, 2019, 2019, CD004680.	2.8	14
197	Activated Coagulation Factor X: A Novel Mitogenic Stimulus for Human Mesangial Cells. Journal of the American Society of Nephrology: JASN, 2001, 12, 891-899.	6.1	14
198	Increasing relevance of donor-specific antibodies in antibody-mediated rejection. Journal of Nephrology, 2013, 26, 237-242.	2.0	14

#	Article	IF	Citations
199	Cryoglobulinemic membranoproliferative glomerulonephritis: beyond conventional therapy. Clinical Nephrology, 2011, 75, 374-379.	0.7	14
200	Conversion to C2 monitoring of cyclosporine A exposure in maintenance kidney transplant recipients: Results at 3 years. American Journal of Kidney Diseases, 2004, 44, 886-892.	1.9	13
201	Micropatterning control of tubular commitment in human adult renal stem cells. Biomaterials, 2016, 94, 57-69.	11.4	13
202	Formalin-fixed paraffin-embedded renal biopsy tissues: an underexploited biospecimen resource for gene expression profiling in IgA nephropathy. Scientific Reports, 2020, 10, 15164.	3.3	13
203	Prediction of chronic kidney disease and its progression by artificial intelligence algorithms. Journal of Nephrology, 2022, 35, 1953-1971.	2.0	13
204	Chronic Renal Failure for Bilateral Spontaneous Kidney Rupture in a Case of Tuberous Sclerosis. American Journal of Nephrology, 1991, 11, 416-421.	3.1	12
205	A comparative study of covariance selection models for the inference of gene regulatory networks. Journal of Biomedical Informatics, 2013, 46, 894-904.	4.3	12
206	Domenico Cotugno and His Interest in Proteinuria. American Journal of Nephrology, 1994, 14, 325-329.	3.1	11
207	Low-density lipoproteins enhance transforming growth factor-betaâ€ƒ1 (TGF-Î²1) and monocyte chemotactic protein-1 (MCP-1) expression induced by cyclosporin in human mesangial cells. Clinical and Experimental Immunology, 1999, 117, 355-360.	2.6	11
208	Medical and surgical complications after kidney transplantation from â€œsuboptimal donorsâ€• one centre's experience. Transplantation Proceedings, 2004, 36, 493-494.	0.6	11
209	A proton nuclear magnetic resonance-based metabolomic approach in IgA nephropathy urinary profiles. Metabolomics, 2013, 9, 740-751.	3.0	11
210	Biomarkers and Precision Medicine in IgA Nephropathy. Seminars in Nephrology, 2018, 38, 521-530.	1.6	11
211	Serum Levels of miR-148b and Let-7b at Diagnosis May Have Important Impact in the Response to Treatment and Long-Term Outcome in IgA Nephropathy. Journal of Clinical Medicine, 2021, 10, 1987.	2.4	11
212	Primary IgA Nephropathy: The Relevance of Experimental Models in the Understanding of Human Disease. Nephron, 1992, 62, 373-381.	1.8	10
213	Ramipril Inhibits in vitro Human Mesangial Cell Proliferation and Platelet-Derived Growth Factor Expression. Nephron Experimental Nephrology, 1999, 7, 229-235.	2.2	10
214	THE ROLE OF TUBULAR CELLS IN THE PROGRESSION OF RENAL DAMAGE: GUILTY OR INNOCENT?. Renal Failure, 2001, 23, 589-596.	2.1	10
215	The urinary sediment beyond light microscopical examination. Nephrology Dialysis Transplantation, 2006, 21, 1482-1485.	0.7	10
216	Coagulation Activation Is Associated with Nicotinamide Adenine Dinucleotide Phosphate Oxidase-Dependent Reactive Oxygen Species Generation in Hemodialysis Patients. Antioxidants and Redox Signaling, 2012, 16, 428-439.	5.4	10

#	Article	IF	Citations
217	Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. Journal of the American Society of Nephrology: JASN, 2022, 33, 291-303.	6.1	10
218	Are lipid-dependent indicators of cardiovascular risk affected by renal transplantation?. Clinical Transplantation, 2000, 14, 139-146.	1.6	9
219	Treatment of glomerulonephritides associated with hepatitis C virus infection. Nephrology Dialysis Transplantation, 2000, 15, 34-38.	0.7	9
220	A mulficentre study of flumequine in the treatment of urinary tract infections. Journal of Antimicrobial Chemotherapy, 1988, 21, 101-106.	3.0	8
221	Acute renal failure in critically ill patients. Intensive Care Medicine, 1999, 25, 1188-1190.	8.2	8
222	The dynamics of kidney donation: Viewpoints from the donor, the recipients, and the transplant team. Kidney International, 2008, 73, 1108-1110.	5.2	8
223	Conversion to C2 monitoring of cyclosporine A exposure in maintenance kidney transplant recipients: Results at 3 years. American Journal of Kidney Diseases, 2004, 44, 886-892.	1.9	8
224	The molecular mechanisms of inflammation and scarring in the kidneys of immunoglobulin A nephropathy. Seminars in Immunopathology, 2021, 43, 691-705.	6.1	8
225	LCAT deficiency: molecular and phenotypic characterization of an Italian family. Journal of Nephrology, 2006, 19, 375-81.	2.0	8
226	Report on the first meeting of the Chairmen of the National and International Registries. Kidney International, 1997, 52, 1422.	5.2	7
227	Primary cerebral lymphoma and membranous nephropathy: A still unreported association. American Journal of Kidney Diseases, 2002, 39, e22.1-e22.5.	1.9	7
228	Epidemiology and Ancestral Difference. , 2009, , 9-19.		7
229	Î²3 adrenergic receptor as potential therapeutic target in ADPKD. Physiological Reports, 2021, 9, e15058.	1.7	7
230	Artificial intelligence in glomerular diseases. Pediatric Nephrology, 2022, 37, 2533-2545.	1.7	7
231	The Role of Polymeric IgA in Complement-Mediated Solubilization of IgG and IgA Immune Complexes. American Journal of Kidney Diseases, 1988, 12, 433-436.	1.9	6
232	Review of Symposium. Transplantation, 2009, 87, S30-S33.	1.0	6
233	Biomarkers and personalized therapy in chronic kidney diseases. Expert Opinion on Investigational Drugs, 2014, 23, 1051-1054.	4.1	6
234	PDGF-B gene single-nucleotide polymorphisms are not predictive for disease onset or progression of IgA nephropathy. Clinical Nephrology, 2007, 67, 65-72.	0.7	6

#	Article	IF	Citations
235	Randomized clinical study to evaluate the effect of personalized therapy on patients with immunoglobulin A nephropathy. CKJ: Clinical Kidney Journal, 2022, 15, 895-902.	2.9	6
236	Bibliometric analysis of the scientific productivity of the Italian Society of Nephrology for a period of five consecutive years (1990-1994). Nephrology Dialysis Transplantation, 1996, 11, 2359-2360.	0.7	5
237	Posttransplant erythrocytosis: A possible nonerythropoietin-mediated mechanism. Transplantation Proceedings, 1997, 29, 223.	0.6	5
238	Angiotensin converting enzyme gene polymorphism in renal transplant patients with IgA nephropathy: relationship with graft function and prevalence of hypertension. Transplantation Proceedings, 1999, 31, 1357-1358.	0.6	5
239	Current structure and organization for renal patient assistance in Italy. Nephrology Dialysis Transplantation, 2007, 23, 1323-1329.	0.7	5
240	Evidence for optimal hemoglobin targets in chronic kidney disease. Journal of Nephrology, 2006, 19, 640-7.	2.0	5
241	Regional variation in C4 phenotype in patients with IgA nephropathy. Journal of Pediatrics, 1990, 116, S72-S77.	1.8	4
242	Cultured Human Mesangial Cells Produce both Type 1 and Type 2 Plasminogen Activator Inhibitors. Thrombosis and Haemostasis, 1995, 74, 1516-1520.	3.4	4
243	For further investigations in IgA nephropathy the approach from phenotype to genotype is welcome. Clinical and Experimental Immunology, 2002, 127, 399-401.	2.6	4
244	Role of miR-422a and kallikrein-related peptidase 4 implicated in the development of lupus nephritis. Do we work in this direction?. Nephrology Dialysis Transplantation, 2016, 31, 683-685.	0.7	4
245	Preeclampsia and fetal triploidy: a rarely reported association in nephrologic literature. Journal of Nephrology, 2002, 15, 74-8.	2.0	4
246	Urinary Epidermal Growth Factor Concentration in Patients Affected by ADPKD. Contributions To Nephrology, 1995, 115, 105-108.	1.1	3
247	Determination of hydroxytyrosol and tyrosol in human urine after intake of extra virgin olive oil produced with an ultrasounds-based technology. Journal of Pharmaceutical and Biomedical Analysis, 2021, 203, 114204.	2.8	3
248	Rituximab induces complete remission in a case of membranous nephropathy associated with hepatitis C virus- related infection. Nephrology Dialysis Transplantation, 2007, 22, 3674-3676.	0.7	2
249	Genome-wide association studies in kidney diseases: Quo Vadis?. Nephrology Dialysis Transplantation, 2009, 24, 3589-3592.	0.7	2
250	Additive effect of cyclosporine and low density lipoproteins on transforming growth factor-Î²1 and monocyte chemotactic protein-1 expression in human mesangial cells. Transplantation Proceedings, 1998, 30, 2051.	0.6	1
251	To the birthday of Giuseppe D'Amico. Nephrology Dialysis Transplantation, 2000, 15, 129-129.	0.7	1
252	Angiotensin IV and Renal Diseases. , 2001, 135, 63-71.		1

#	Article	IF	Citations
253	Therapeutic aspects of IgA nephropathy: an overview. Nephrology, 2002, 7, S156.	1.6	1
254	EARLY WITHDRAWAL OF CYCLOSPORINE IMPROVES 1-YEAR KIDNEY GRAFT STRUCTURE AND FUNCTION IN SIROLIMUS-TREATED PATIENTS: RESPONSE TO THE AUTHORS. Transplantation, 2004, 77, 162-163.	1.0	1
255	Acute rejection of non-functional allograft in kidney transplant recipients with hepatitis C treated with peginterferon alpha-2a: Reply. Journal of Hepatology, 2008, 49, 462-463.	3.7	1
256	Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrology Dialysis Transplantation, 2010, 25, 1363-1364.	0.7	1
257	Transplantation - basic. Nephrology Dialysis Transplantation, 2012, 27, ii517-ii524.	0.7	1
258	SP051EXOSOMAL SHUTTLE RNA IN URINARY EXTRACELLULAR VESICLES AS BIOMARKER OF CLEAR CELL RENAL CELL CARCINOMA. Nephrology Dialysis Transplantation, 2015, 30, iii397-iii397.	0.7	1
259	MicroRNAs in Kidney Diseases. , 2016, , 107-138.		1
260	MO260PERFORMANCE ANALYSIS OF AN ARTIFICIAL NEURAL NETWORK TOOL TO PREDICT ESKD IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IGAN). Nephrology Dialysis Transplantation, 2021, 36, .	0.7	1
261	Stem cells: reparative medicine and nephrology. Journal of Nephrology, 2003, 16 Suppl 7, S1-5.	2.0	1
262	Report on the 2nd European Meeting on Complement in Human Disease. Complement and Inflammation, 1989, 6, 94-95.	0.7	0
263	Therapeutic aspects of IgA nephropathy: an overview. Nephrology, 2002, 7, S156-S163.	1.6	0
264	Response to â€˜The importance of donor privacyâ€™. Kidney International, 2008, 74, 1359.	5.2	0
265	Thrombin induces complement production and modulates T cell responses by dendritic cells (DCs) in kidney transplant recipients with delayed graft function (DGF). Immunobiology, 2012, 217, 1214.	1.9	0
266	Reply: The Importance of Testing Anti-IL-17 Antibodies from Different Suppliers. American Journal of Transplantation, 2012, 12, 506.	4.7	0
267	SP054ABNORMAL METHYLATED DNA REGIONS INDICATE AN ATYPICAL RESPONSE OF THE CD4+ T CELLS IN IGA NEPHROPATHY PATIENTS. Nephrology Dialysis Transplantation, 2015, 30, iii398-iii398.	0.7	0
268	IgAN Genetic Risk Score in the Clinical Setting. Kidney International Reports, 2020, 5, 1627-1629.	0.8	0
269	A Critical Revision of the Supportive Therapy in IgA Nephropathy. Juntendo Medical Journal, 2014, 60, 251-257.	0.1	0
270	MicroRNAs in Kidney Diseases. , 2015, , 1-32.		0

#	Article	IF	Citations
271	New directions in the pathogenesis of primary erythrocytosis in IgAN. EBioMedicine, 2022, 76, 103834.	6.1	0
272	FC048: New Tool to Predict the Clinical Course and Renal Failure in Patients with Immunoglobulin a Nephropathy. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0